Gene therapy for retinal dystrophy may increase inflammation in some patients
- Posted on: Nov 23 2022
- Leave a response
Some patients undergoing voretigene neparvovec treatment for RPE65-related retinal dystrophy may have increased risk of post-treatment inflammation, including those with high BMIs or a family history of inflammatory responses to gene therapy.
Source: AAO
Posted in: Uncategorized
